A
ABUS
Arbutus Biopharm
4.480
-0.040-0.89%After Hours: 4.450 -0.030 -0.67%19:56 04/02 EDT
OPEN/PREV CLOSE4.400/4.520
TODAY RANGE4.374-4.540
VOL612.47K
MARKET CAP875.74M
52 WEEK RANGE2.705-5.10
AVG VOL (3M)2.21M
% TURNOVER0.31%
TURNOVER--
P/E (TTM)-25.6293
% RANGE3.67%
EPS(TTM)-0.1748
P/E(FORWARD)-27.5184
P/B11.26
BVPS0.3977
DIVIDEND--
P/S61.29
BETA--
DIV YIELD0.00%
FREE FLOAT MKT CAP687.22M
SHARES OUTSTANDING195.48M
NEXT EARNINGS05/12-05/18
FREE FLOAT153.40M
LOT SIZE1
EX-DATE11/04/2010
News
Press Releases
Financial Reports
Profile
Simply Wall St·03/23 22:13
Arbutus Biopharma (ABUS) Q3 Loss And Revenue Drop Challenge Bullish Profitability Narratives
TipRanks·03/23 12:11
Arbutus Boosted by $2.25 Billion LNP Settlement and Hepatitis B Trial Progress
Dow Jones·03/23 11:31
*Arbutus Biopharma 2025 Rev $14.1M >ABUS
Barchart·03/23 06:39
Arbutus: Q4 Earnings Snapshot
Reuters·03/05 11:03
Moderna Settles Arbutus Genevant Patent Litigation for $950 Million
NASDAQ·03/04 20:27
Notable Wednesday Option Activity: GTLB, ABUS, TTWO
TipRanks·03/04 16:56
Midday Fly By: Stocks climb as oil prices pull back
TipRanks·03/04 16:20
Morning News Wrap-Up 3/4/26: Wednesday’s Biggest Stock Market Stories!
Seeking Alpha·03/04 16:05
Why Moderna's $950M Patent Bill Is A Small Price For Pipeline Freedom
TipRanks·03/04 14:40
Unusually active option classes on open March 4th
Seeking Alpha·03/04 14:18
Moderna gains as Arbutus/ Genevant settlement removes major financial risk
TipRanks·03/04 14:02
Video: Moderna advances as settlement seen removing share overhang
Same Industry
Name/Symbol
Change%
Price
Contact Us
Contact Number :+852 3852 8500Monday 7:00 AM - Saturday 9:00 AM (HKT)
Service Email :service@webull.hkOnline Support: Monday - Friday: 9:00 - 16:00; 22:30 - 5:00 (HKT)
Business Cooperation :marketinghk@webull.hkRisk Disclosure: The content of this page is not an investment advice and does not constitute any offer or solicitation to offer or recommendation of any investment product. It is for general purposes only and does not take into account your individual needs, investment objectives and specific financial circumstances. All investments involve risk and the past performance of securities, or financial products does not guarantee future results or returns. Keep in mind that while diversification may help spread risk it does not assure a profit, or protect against loss, in a down market. There is always the potential of losing money when you invest in securities, or other financial products. Investors should consider their investment objectives and risks carefully before investing. For more details, please refer to risk disclosure.
Webull Securities Limited is licensed with the Securities and Futures Commission of Hong Kong (CE No. BNG700) for carrying out Type 1 License for Dealing in Securities, Type 2 License for Dealing in Futures Contracts and Type 4 License for Advising on Securities.
Webull Securities Limited is licensed with the Securities and Futures Commission of Hong Kong (CE No. BNG700) for carrying out Type 1 License for Dealing in Securities, Type 2 License for Dealing in Futures Contracts and Type 4 License for Advising on Securities.
Language
English
©2026 Webull Securities Limited. All rights reserved.